JP2022550569A - ドロナビノールの経皮送達 - Google Patents

ドロナビノールの経皮送達 Download PDF

Info

Publication number
JP2022550569A
JP2022550569A JP2022520408A JP2022520408A JP2022550569A JP 2022550569 A JP2022550569 A JP 2022550569A JP 2022520408 A JP2022520408 A JP 2022520408A JP 2022520408 A JP2022520408 A JP 2022520408A JP 2022550569 A JP2022550569 A JP 2022550569A
Authority
JP
Japan
Prior art keywords
once
dronabinol
days
transdermal
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550569A5 (https=
JPWO2021067806A5 (https=
Inventor
エム．プラコギアンニス フォティオス
ラザー タマンナ
モディ ニサーグ
ボロビンスカヤ マリナ
Original Assignee
スタートン セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スタートン セラピューティクス，インコーポレイティド filed Critical スタートン セラピューティクス，インコーポレイティド
Publication of JP2022550569A publication Critical patent/JP2022550569A/ja
Priority to JP2025141377A priority Critical patent/JP2026009105A/ja
Publication of JP2022550569A5 publication Critical patent/JP2022550569A5/ja
Publication of JPWO2021067806A5 publication Critical patent/JPWO2021067806A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022520408A 2019-10-03 2020-10-02 ドロナビノールの経皮送達 Pending JP2022550569A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025141377A JP2026009105A (ja) 2019-10-03 2025-08-27 ドロナビノールの経皮送達

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910255P 2019-10-03 2019-10-03
US62/910,255 2019-10-03
PCT/US2020/054070 WO2021067806A1 (en) 2019-10-03 2020-10-02 Transdermal delivery of dronabinol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025141377A Division JP2026009105A (ja) 2019-10-03 2025-08-27 ドロナビノールの経皮送達

Publications (3)

Publication Number Publication Date
JP2022550569A true JP2022550569A (ja) 2022-12-02
JP2022550569A5 JP2022550569A5 (https=) 2026-01-14
JPWO2021067806A5 JPWO2021067806A5 (https=) 2026-01-14

Family

ID=72964852

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520408A Pending JP2022550569A (ja) 2019-10-03 2020-10-02 ドロナビノールの経皮送達
JP2025141377A Pending JP2026009105A (ja) 2019-10-03 2025-08-27 ドロナビノールの経皮送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025141377A Pending JP2026009105A (ja) 2019-10-03 2025-08-27 ドロナビノールの経皮送達

Country Status (8)

Country Link
US (2) US20210100737A1 (https=)
EP (1) EP4037663A1 (https=)
JP (2) JP2022550569A (https=)
CN (2) CN114650809A (https=)
AU (1) AU2020358869A1 (https=)
CA (1) CA3156257A1 (https=)
MX (1) MX2022004033A (https=)
WO (1) WO2021067806A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409131B2 (en) * 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) * 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
EP4046630A1 (en) * 2021-02-18 2022-08-24 LTS Lohmann Therapie-Systeme AG Tts-formulation with thc
JP2024514362A (ja) * 2021-04-22 2024-04-01 パイク セラピューティクス インコーポレイテッド 慢性疼痛の処置のための経皮医薬製剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111377A1 (en) * 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
JP2011505382A (ja) * 2007-11-30 2011-02-24 オールトランツ インコーポレイティド テトラヒドロカンナビノールのプロドラッグ、テトラヒドロカンナビノールのプロドラッグを含む組成物、及び同一のものを使用する方法

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US6113940A (en) 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
US5804592A (en) * 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
DE19918106A1 (de) 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
JP2003504321A (ja) 1999-07-08 2003-02-04 オーランド・ハン リポソーム被包カンナビノイドの肺送達
US20050042271A1 (en) 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
JP2003524652A (ja) 2000-02-29 2003-08-19 ツァン，ツィエ 改良された経皮薬剤パッチ
US20020019421A1 (en) 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
EP1331929A1 (en) 2000-11-06 2003-08-06 Samyang Corporation Transdermal drug delivery system with improved water absorbability and adhesion properties
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
US20180042842A1 (en) 2001-02-14 2018-02-15 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US6503532B1 (en) 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
GB2377218A (en) 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
FI113340B (fi) 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US10538373B2 (en) 2002-08-14 2020-01-21 Gw Pharma Limited Pharmaceutical formulation
SI1542657T1 (sl) 2002-08-14 2012-04-30 Gw Pharma Ltd Kanabinoidne kapljevite formulacije za sluzniäśno administracijo
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
US20050070596A1 (en) 2003-05-12 2005-03-31 David Baker Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
EP1559423A1 (en) 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US7671052B2 (en) 2004-10-05 2010-03-02 Adolor Corporation Phenyl derivatives and methods of use
WO2006044645A2 (en) 2004-10-13 2006-04-27 Adolor Corporation Sulfamoyl benzamides and methods of their use
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
CN101175403A (zh) * 2005-05-13 2008-05-07 尤尼麦德制药公司 延迟性化疗引起的恶心和呕吐的屈大麻酚治疗
BRPI0610364A2 (pt) * 2005-05-13 2010-06-15 Unimed Pharmaceuticals Inc tratamento, com dronabinol, de náusea e vÈmito retardados induzidos por quimioterapia
US20060263421A1 (en) 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
US20070083186A1 (en) 2005-09-30 2007-04-12 Darrick Carter Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
GB2431105A (en) 2005-10-12 2007-04-18 Gw Pharma Ltd Cannabinoids for the treatment of pulmonary disorders
GB2432312A (en) 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
US7544676B2 (en) 2005-11-10 2009-06-09 Adolor Corporation Sulfamoyl benzamides and methods of their use
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
US8481085B2 (en) 2006-06-15 2013-07-09 Gw Pharma Limited Pharmaceutical compositions comprising cannabigerol
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
CA2657332A1 (en) 2006-07-14 2008-01-17 Wine, Harvey Transdermal formulations of synthetic cannabinoids and nano colloidal silica
WO2008019146A2 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
CA2664935A1 (en) 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
WO2008063625A2 (en) 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
CA2698752A1 (en) 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
GB2475183B (en) 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2285362B1 (en) 2008-06-19 2017-08-09 LTS LOHMANN Therapie-Systeme AG Composition for transdermal delivery of cationic active agents
WO2009158477A1 (en) 2008-06-25 2009-12-30 Us Worldmeds Llc Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
MX2011011514A (es) 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
MX2011011445A (es) 2009-04-29 2011-11-18 Univ Kentucky Res Found Composiciones que contienen cannabinoides y metodos para su uso.
PT2473475T (pt) 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
US20130210786A1 (en) 2010-07-20 2013-08-15 Patrick Alexander Howson Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
JP5073124B2 (ja) 2010-12-07 2012-11-14 祐徳薬品工業株式会社 ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤
US8642645B2 (en) 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
US20130022687A1 (en) 2011-07-19 2013-01-24 Fitzgerald Jr John James Topical transdermal method for delivering nutrients through the skin for expedited wound healing
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
EP2609912A1 (en) 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols
ES2739194T3 (es) 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
WO2015066302A2 (en) 2013-10-30 2015-05-07 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods of use, and methods of treatment
US10064905B1 (en) 2013-11-11 2018-09-04 Ilysm, LLC Pharmaceutical preparation
US10555927B2 (en) 2013-11-11 2020-02-11 Ilysm, LLC Compositions and methods for enhancing sexual pleasure and performance
GB2524469A (en) 2014-02-14 2015-09-30 Kind Consumer Ltd A cannabinoid inhaler and composition therefor
US9918961B2 (en) 2014-02-19 2018-03-20 Kind Consumer Limited Cannabinoid inhaler and composition therefor
ES2989832T3 (es) 2014-03-18 2024-11-27 Izun Pharmaceuticals Corp Composiciones de cannabinoides unidos a proteínas
US20160022627A2 (en) 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
US20160271252A1 (en) 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
AU2015279612A1 (en) 2014-06-27 2017-02-02 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
EP3160565B1 (en) 2014-06-30 2021-08-18 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
US20160000843A1 (en) 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
US20160039591A1 (en) 2014-07-22 2016-02-11 Craig E. Kinzer Packaging systems, devices, methods, and composition including cannabinoid unit dose forms
CA2996626A1 (en) 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
CA2859930A1 (en) 2014-09-22 2016-03-22 Antony Paul Hornby A cannabis topical from heat treated cocount oil
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB201418713D0 (en) 2014-10-21 2014-12-03 Kymab Ltd Bindings Proteins
JP6676062B2 (ja) 2014-11-03 2020-04-08 ラモト アト テルーアビブ ユニバーシティー リミテッド 認知低下を処置するための方法
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
WO2016092539A1 (en) 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
WO2016103254A1 (en) 2014-12-21 2016-06-30 One World Cannabis Ltd Use of cannabis to treat psoriasis
WO2016109624A1 (en) 2014-12-30 2016-07-07 University Of Houston System Pharmaceutical compositions
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
HK1247084A1 (zh) 2015-02-02 2018-09-21 APIRx Pharmaceuticals, LLC 大麻素和糖醇复合物，制备和使用的方法
AU2016215094B2 (en) 2015-02-05 2019-09-26 Colorado Can Llc Purified CBD and CBDA, and methods, compositions and products employing CBD or CBDA
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
CA2979049A1 (en) 2015-03-10 2016-09-15 Eleusis Benefit Corporation, Pbc Lsd for the treatment of alzheimer's disease
WO2016147186A1 (en) 2015-03-19 2016-09-22 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
BR112018001310A2 (en) 2015-07-22 2018-09-11 Phytopharma International Ltd. bee-ingestible compositions, methods of use thereof for the production of honey and honey produced by these
US9827282B2 (en) 2015-07-24 2017-11-28 Bao Tran Medication dispensing system
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CA2995418A1 (en) 2015-08-11 2017-02-16 KannaInnovations LLC Topical compositions comprising hydroxy acids and cannabinoids for skin care
US10272125B2 (en) 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
EP3355874A4 (en) 2015-09-30 2019-06-12 George Edward Hoag TOPICAL ANALGETIC FORMULATIONS, MANUFACTURE AND METHOD FOR USE THEREOF
US10695287B2 (en) 2015-11-17 2020-06-30 Cersci Therapeutics, Inc. AMPK agonist topical medication for the treatment of certain specific medical conditions, methods of use thereof and wound dressing employing the same
US20170202895A1 (en) 2016-01-18 2017-07-20 Kevin Anthony Hugh Cannabis Pellets
US10338355B2 (en) 2016-02-05 2019-07-02 Largan Precision Co., Ltd. Lens assembly
CA3283924A1 (en) 2016-03-16 2025-11-29 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition
AU2017250001B2 (en) 2016-04-12 2017-12-14 Little Green Pharma Ltd Liposomal preparation and methods of treatment
LT6486B (lt) 2016-04-13 2018-01-10 UAB "SatiMed" Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui
CA3021144C (en) 2016-04-19 2024-04-09 Canabuzz-Med Cannabis-enriched enzymatically treated therapeutic composition
EP3928776B1 (en) 2016-04-22 2025-11-12 Spoke Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
IT201600068779A1 (it) 2016-07-01 2018-01-01 Datalogic IP Tech Srl Lettore di codici ottici
GB2551985B (en) 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
US20190224118A1 (en) 2016-07-11 2019-07-25 Intec Pharma Ltd. Oral gastroretentive formulations and uses thereof
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
CN110072523A (zh) 2016-09-07 2019-07-30 格利亚有限责任公司 通过脑神经的药理皮肤激活来治疗与神经退行性病症相关的症状
US10869842B1 (en) 2016-09-07 2020-12-22 David P Summers Transdermal delivery of pharmaceutical agents
AU2017344040A1 (en) 2016-10-11 2019-04-18 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
EP3525764A4 (en) 2016-10-12 2020-05-13 Columbia Care LLC ORAL COMPOSITION OF EXTRACTED CANNABINOIDS AND METHOD FOR USE THEREOF
EP3534893A1 (en) 2016-11-02 2019-09-11 To Pharmaceuticals LLC Combination therapy of cbd and copaxone
WO2018083695A2 (en) 2016-11-02 2018-05-11 Tikun Olam Ltd Combination therapies
WO2018085794A1 (en) 2016-11-07 2018-05-11 Avidas Pharmaceuticals Llc Therapeutic cannabinoid formulations and methods for their use
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US11147799B2 (en) 2016-12-06 2021-10-19 Jan Marius Keppel Hesselink Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain
US20190321355A1 (en) 2016-12-15 2019-10-24 Sharon Anavi-Goffer Treatment of mental, movement and behavioral disorders
US20180311180A1 (en) 2016-12-29 2018-11-01 International Bioceutical Co. LLC Modular Transdermal Delivery Systems for the Treatment of Pain and Inflammation
JP2020518325A (ja) 2016-12-29 2020-06-25 ピュア レイシオス ホールディングス， インコーポレイテッド モジュール式経皮送達システムならびに製造および使用の関連する方法
US20180311181A1 (en) 2016-12-29 2018-11-01 International Bioceutical Co. LLC Modular Transdermal Delivery Systems for the Treatment of Insomnia and Anxiety
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
US10675264B2 (en) 2017-02-07 2020-06-09 Elevate Technologies Llc Terpene-based compositions, methods of preparations and uses thereof
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
AU2018273410A1 (en) 2017-05-26 2020-01-16 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
US10945967B2 (en) 2017-05-30 2021-03-16 Jae Wang. Song Formulations of a transdermal patch for pain management
CA3065167A1 (en) 2017-05-31 2018-12-06 Phytecs, Inc. Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
CA3103178A1 (en) 2017-06-27 2019-01-03 Enviro BioMedical Laboratories Inc. Blended cannabis compounds and methods of making the same
CA3068383A1 (en) 2017-06-28 2019-01-03 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid product for women health
CA3013573A1 (en) 2017-08-08 2019-02-08 Steven Bermudez Method for reduction, suppression, or elimination of anxiety or marijuana/cannabis effects and related marijuana/cannabis product by process
CA3071497A1 (en) 2017-08-13 2019-02-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition and method of treatment
IL301622A (en) 2017-08-14 2023-05-01 Zynerba Pharmaceuticals Inc Methods for treating degenerative joint disease with cannabidiol gel through the skin
EP3675849A4 (en) 2017-09-02 2021-11-24 Scientific Holdings, LLC TETRAHYDROCANNABINOL MODULATORS
CN109498606A (zh) 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
BR112020004947A2 (pt) 2017-09-19 2020-09-15 Zynerba Pharmaceuticals, Inc. canabidiol transdérmico sintético para o tratamento de epilepsia focal em adultos
ES2907325T3 (es) 2017-09-28 2022-04-22 Zynerba Pharmaceuticals Inc Tratamiento de síndrome del cromosoma X frágil y autismo con cannabidiol
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
US20190110981A1 (en) 2017-10-17 2019-04-18 Life Tech Global, Llc Cannabinoid Patch
US10307392B2 (en) 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
US12364668B2 (en) 2017-11-15 2025-07-22 The Regents Of The University Of California Treatment of opioid use disorder, opioid withdrawal symptoms, and chronic pain
WO2019130215A1 (en) 2017-12-27 2019-07-04 To Pharmaceuticals Llc Cannabis compositions for the treatment of inflammatory skin disorders
US10722545B2 (en) 2018-01-01 2020-07-28 Alexander Kariman Compound and method for treatment of movement disorders
GB2572126B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
LU101385B1 (en) 2018-01-12 2020-01-30 Nutrae Llc Encapsulated Cannabinoid Formulations For Oral Delivery
US11759473B2 (en) 2018-02-16 2023-09-19 American Nano, LLC Topical compositions incorporating silica fibers
BR112020017023A2 (pt) 2018-02-23 2021-03-02 Nicola Michael Spirtos terapêutica à base de cannabis e método de uso
WO2019191830A1 (en) 2018-04-04 2019-10-10 Vincenzo Maida Topical cannabinoid formulations and instillates, kits, and methods for treating integumentary wounds, and uses thereof
AU2019260810A1 (en) 2018-04-27 2020-11-19 Remy Biosciences, Inc. New medical devices, delivery vehicles and manufacturing thereof
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US20190328884A1 (en) 2018-04-30 2019-10-31 Chemic Laboratories, Inc. Compositions and methods of their use
WO2019224824A1 (en) 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
US10864189B2 (en) 2018-06-29 2020-12-15 Jenna Borok Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care
GB201811834D0 (en) 2018-07-19 2018-09-05 Medherant Ltd Patch
GB201811833D0 (en) 2018-07-19 2018-09-05 Medherant Ltd Patch
US20200054887A1 (en) 2018-08-15 2020-02-20 Bruce H. Levin Topical Therapeutics
US10695301B2 (en) 2018-09-04 2020-06-30 Babak Ghalili Veterinary cannabinoid and menthol compositions and methods
CA3060926A1 (en) 2018-09-06 2020-03-06 NuVessl, Inc. Method of using cannabinoids encapsulated in phospholipid carriers for transmucosal and transdermal administration
US11357958B2 (en) 2018-10-25 2022-06-14 Medtronic Vascular, Inc. Devices and techniques for cardiovascular intervention
US12240852B2 (en) 2018-12-11 2025-03-04 Regents Of The University Of Michigan Co-crystals, method and apparatus for forming the same
MX2021007076A (es) 2018-12-14 2021-08-11 Zynerba Pharmaceuticals Inc Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
US11660283B2 (en) 2018-12-19 2023-05-30 Joyn Botanicals Ltd. Cannabinoid-containing composition
AU2019412825A1 (en) 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
WO2020142692A1 (en) 2019-01-04 2020-07-09 Columbia Care Llc Topical formulations having cannabinoid
GB2580653A (en) 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
AU2020215150B8 (en) 2019-01-30 2025-07-03 Diamond Therapeutics Inc. Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders
US20210015740A1 (en) 2019-03-04 2021-01-21 Michael Harvey Greenspan Topical cannabinoid compositions, delivery systems, and uses for pain relief
WO2020183350A1 (en) 2019-03-12 2020-09-17 Radient Technologies Innovations Inc. Transdermal patch kit with transdermal dosage units
KR20220003519A (ko) 2019-03-26 2022-01-10 윈산토르, 아이엔씨. 말초 신경병증 치료를 위한 국소 제형
US20220339119A1 (en) 2019-04-03 2022-10-27 Ely Nigel Stratemeyer-Trinczek Transdermal medicament
US20200330379A1 (en) 2019-04-17 2020-10-22 Navinta NV, Inc. Non-oral cannabinoid formulation and method of treatment
US20200345653A1 (en) 2019-05-02 2020-11-05 Kenda Hansen Transdermal Composition
US20200345685A1 (en) 2019-05-02 2020-11-05 Christopher Ayo Otiko Topical application of medical cannabis
CA3138630A1 (en) 2019-05-02 2020-11-05 Betterlife Pharma Inc. Cannabinoid stock transdermal formulations
US20200352849A1 (en) 2019-05-07 2020-11-12 Adam M. Rotunda Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment
EP3975703A4 (en) 2019-05-28 2023-07-12 Tech Swerve LLC PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHOD OF USE
US11026896B2 (en) 2019-06-18 2021-06-08 Dyve Biosciences, Inc. Transdermal penetrant formulations containing cannabidiol
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
WO2021003467A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
ES2998817T3 (en) 2019-08-05 2025-02-21 Cs Medica As Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
CN114401713A (zh) 2019-09-17 2022-04-26 Zyne制药公司 在发育性和癫痫性脑病中的行为损伤的治疗
CN114650809A (zh) * 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) * 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US11951079B2 (en) 2019-10-03 2024-04-09 Kongkrit Chaiyasate Topical cannabidiol composition
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US11318093B2 (en) 2019-11-08 2022-05-03 Pac-Dent, Inc. Dental topical anesthetic gel
US20210145764A1 (en) 2019-11-15 2021-05-20 Brigham Young University Compositions of cannabidiol (cbd), and/or polyphenols, and methods for the prevention and/or treatment of skin, muscle, nerve and inflammatory disorders, and biological factors and functions in mammals
US20210244680A1 (en) 2020-02-10 2021-08-12 Ghassan S. Kassab Wearable liposomal cannabidiol transdermal patch
CA3170545A1 (en) 2020-02-11 2021-08-19 Babak Ghalili Cannabinoid and menthol transdermal delivery systems and methods
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021177940A1 (en) 2020-03-03 2021-09-10 Babak Ghalili Cannabinoid and menthol gel compositions, patches and methods
WO2021236782A1 (en) 2020-05-19 2021-11-25 Mig Usa, Llc Topical compositions and methods for treating pain
JP2023552390A (ja) 2020-12-03 2023-12-15 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 難治性発作の治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111377A1 (en) * 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
JP2011505382A (ja) * 2007-11-30 2011-02-24 オールトランツ インコーポレイティド テトラヒドロカンナビノールのプロドラッグ、テトラヒドロカンナビノールのプロドラッグを含む組成物、及び同一のものを使用する方法

Also Published As

Publication number Publication date
AU2020358869A1 (en) 2022-04-14
US20210100737A1 (en) 2021-04-08
EP4037663A1 (en) 2022-08-10
US12409132B2 (en) 2025-09-09
CN120585717A (zh) 2025-09-05
WO2021067806A1 (en) 2021-04-08
CA3156257A1 (en) 2021-04-08
CN114650809A (zh) 2022-06-21
MX2022004033A (es) 2022-07-19
US20210220325A1 (en) 2021-07-22
JP2026009105A (ja) 2026-01-19

Similar Documents

Publication Publication Date Title
US12186280B2 (en) Pharmaceutical composition and method for treating seizure disorders
US12409132B2 (en) Transdermal delivery of dronabinol
US12409131B2 (en) Transdermal delivery of dronabinol
US20260076921A1 (en) Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis
JP5403948B2 (ja) メマンチン含有経皮吸収製剤
AU5718494A (en) Enhanced pharmaceutical compositions for skin penetration
US20240261235A1 (en) Pharmaceutical Composition And Method For Treating Seizure Disorders
EP4138831A1 (en) Oral delivery system comprising hydroxychloroquine and/or chloroquine
WO2022215030A1 (en) Pharmaceutical composition and method for treating seizure disorders
WO2021211558A1 (en) Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders
HK40084062A (en) Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
KR20020008730A (ko) 남성호르몬 경피흡수 조성물 및 이를 함유한 경피흡수패취제

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250827

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260113